Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Follow-Up Questions
Jupiter Neurosciences Inc 的 CEO 是誰？
Mr. Christer Rosen 是 Jupiter Neurosciences Inc 的 Chairman of the Board，自 2016 加入公司。
JUNS 股票的價格表現如何？
JUNS 的當前價格為 $1.44，在上個交易日 increased 了 0.7%。
Jupiter Neurosciences Inc 的主要業務主題或行業是什麼？
Jupiter Neurosciences Inc 屬於 Pharmaceuticals 行業，該板塊是 Health Care
